basiliximab + tacrolimus

Basiliximab + tacrolimus is a combination immunosuppressive regimen used primarily in solid organ transplantation, such as kidney and liver transplants. Basiliximab is a chimeric monoclonal antibody that targets the alpha-chain (CD25) of the interleukin-2 receptor on activated T-lymphocytes, thereby inhibiting IL-2-mediated activation and proliferation of T-cells. Tacrolimus is a calcineurin inhibitor that suppresses immune responses by inhibiting T-cell activation through blockade of interleukin-2 transcription. Together, these agents reduce the risk of acute cellular rejection (ACR) after transplantation by providing complementary mechanisms to suppress immune activity against transplanted organs. This combination has been shown to be effective in reducing rejection episodes without significantly increasing adverse effects or infection rates.